• <acronym id="pmolm"><strong id="pmolm"></strong></acronym>
  • <track id="pmolm"><ruby id="pmolm"></ruby></track>
      1. <acronym id="pmolm"><label id="pmolm"></label></acronym>
        <acronym id="pmolm"><strong id="pmolm"></strong></acronym>
        <td id="pmolm"></td>
        中文版 English
        Product Center
        Home >> Product Center >> Cardiovascular diseases >> Cardiac troponin I / heart-type fatty acid binding protein (cTnI-HFABP) test kit
        • Name: Cardiac troponin I / heart-type fatty acid binding protein (cTnI-HFABP) test kit

        Description]: the product can be used with Bioda immune detector to quantitatively detect troponin I and heart-type fatty acid binding protein in human whole blood, serum and plasma, and it can provide reference for clinical diagnosis of myocardial infarction.
        ● The cTnI and HFABP of patients with chest pain who have local bleeding can be detected for the early diagnosis of myocardial infarction
        ● The sensitivity of HFABP is significantly higher than cTnI in patients with onset symptoms within 4 hours
        ● In order to reduce the diagnosis risk of AMI patients in development, the combined detection of cTnI and HFABP can provide a good diagnosis method

        [Detailed information]: Bioda cTnI-HFABP produced by our company is an in vitro diagnostic reagent used to detect cTnI and HFABP protein in human whole blood, serum and plasma.

        In intact myocardial cell membrane, cTnI can not enter the blood circulation through the cell membrane, so there is no or very low cTnI in the blood of healthy people. In patients with acute myocardial infarction, the cTnI released to the circulatory system will exceed the normal upper limit about 4-6h after the onset of symptom; in 12-24 h after such onset, the cTnI concentration will reach the peak value, and then maintain a high level for 6-10 days. Since cTnI has high myocardial specificity and sensitivity, it is a relatively good definitive myocardial marker for early AMI diagnosis, prognosis evaluation and early unstable angina pectoris diagnosis.

        H-FABP is a kind of small molecular weight (14.9kd) plasmosin, which is rich in myocardial cells. Generally, H-FABP is very little in the plasma and urine of normal human, but it can be released into the blood rapidly when the myocardial cells are injured. The plasma concentration of H-FABP begins to rise in 1.3-3 h after the onset of AMI, reaches the peak in 8 h, and returns to normal in 12-24 h. The sensitivity of H-FABP is significantly higher than that of cTnI and CK-MB within 1-4 h after the onset of AMI. There is no significant difference in specificity, and the accuracy of H-FABP is significantly higher than that of cTnI, CK-MB and MYO. Therefore, H-FABP can be used as an indicator of early AMI.

        I-Through the joint detection of cTnI and HFABP, the detection results are more sensitive, accurate and specific, thus greatly improving the timeliness and accuracy of clinical detection.
        [Reaction time]: 12 min
        [Detection range]: cTnI: 0.05-50ng/ml, HFABP: 1-120ng/ml
        [Clinical significance]: diagnosis of myocardial injury and acute myocardial infarction (AMI)

        [Applicable departments]: Outpatient Department, Emergency Department, Cardiology Department, Thoracic Surgery Department, Ambulance, Ward, ICU, Geriatrics Department

        [Interpretation method]:

        Detection results (ng/ml)


        Detection results (ng/ml)







        Myocardial injury


        Myocardial injury or AMI


        Acute myocardial infarction (AMI)

        Bioda Diagnostics(Wuhan) Co.,LTD. all rights reserved 鄂ICP备19013949号-1 Home News Products Contact